Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

We Claim:

Claims 1-25 (Cancelled).

26. (Currently amended) A monovalent influenza vaccine composition comprising an influenza virus component that is a low dose of egg-derived, purified, whole influenza virus antigen from an influenza virus strain that is associated with a pandemic outbreak, or has the potential to be associated with a pandemic outbreak, in combination with a suitable adjuvant, wherein the low antigen dose is less than 15 μg of haemagglutinin per dose, and wherein the adjuvant is at least one aluminium salt.

27. (Cancelled).

28. (Cancelled).

29. (Previously presented) The vaccine composition according to claim 26, wherein the adjuvant is a mixture of aluminium hydroxide and aluminium phosphate.

30. (Previously presented) The vaccine composition according to claim 29, wherein the amount of aluminium phosphate exceeds the amount of aluminium hydroxide.

31. (Previously presented) The vaccine composition according to claim 26, wherein the aluminium salts are present in the range of from about 0.4 to about 1.0 mg per vaccine dose.

32. (Previously presented) The vaccine composition according to claim 26, wherein the low antigen dose is less than 10 μg of haemagglutinin per dose.

33. (Previously presented) The vaccine composition according to claim 32, wherein the antigen dose is between 0.1 μg and 7.5 μg or between 1 and 5 μg of haemagglutinin per dose.

34. (Previously presented) The vaccine composition according to claim 26, wherein the influenza virus antigen is substantially free of host cell contamination.

35. (Previously presented) The vaccine composition according to claim 26, wherein the influenza virus component is purified by a method that includes a protease incubation step to digest non-influenza virus proteins.

36-40. (Cancelled).

41. (Currently amended) A method for the production of an influenza vaccine for a pandemic situation, said method comprising admixing egg-derived, purified, whole influenza virus antigen from a single influenza virus strain that is associated with a pandemic outbreak or has the potential to be associated with a pandemic outbreak, with a suitable adjuvant, wherein the adjuvant is at least one aluminium salt, and providing vaccines lots that contain less than 10 μg influenza haemagglutinin antigen per dose.

42-43. (Cancelled).

44. (Previously presented) The vaccine composition of claim 26, wherein the antigen is selected from an H2 antigen and an H5 antigen.

45. (Cancelled).

46. (Previously presented) The method of claim 41, wherein the antigen is selected from an H2 antigen and an H5 antigen.

47-50. (Cancelled).

51. (Currently amended) A method for treating a patient with a monovalent influenza vaccine composition, said method comprising the step of administering to the patient an influenza virus component that is a low dose of egg-derived, purified, whole influenza virus antigen from an influenza virus strain that is associated with a pandemic outbreak, or has the potential to be associated with a pandemic outbreak, in combination with a suitable adjuvant, wherein the low antigen dose is less than 15 μg of haemagglutinin per

dose or no more than 15 μg per administered dose of vaccine, and wherein the adjuvant is at least one aluminium salt.

52. (Previously presented) The method according to claim 51, wherein there is more than one separate administered dose, the total of which is less than 15 μg of haemagglutinin or no more than 15 μg of vaccine.

53. (Previously presented) The vaccine composition according to claim 26, wherein the adjuvant is chosen from the group of: aluminium hydroxide and aluminium phosphate.

54. (Previously presented) The vaccine composition according to claim 44, wherein the H2 antigen is H2N2, and the H5 antigen is H5N1.

55. (Previously presented) The method according to claim 46, wherein the H2 antigen is H2N2, and the H5 antigen is H5N1.

56. (Currently amended) A kit comprising a monovalent influenza vaccine composition, wherein said composition comprises an influenza virus component that is a low dose of less than 15 μg of haemagglutinin per dose, of egg-derived, purified, whole dose influenza virus antigen from an influenza virus strain that is associated with a pandemic outbreak, or has the potential to be associated with a pandemic outbreak, in combination with a suitable adjuvant, wherein said kit contains less than 10 μg influenza haemagglutinin antigen per administered dose, and wherein the adjuvant is at least one aluminium salt.